Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in Melanoma or RCC Brain Metastases
NCT04955743Phase 2Terminated
- Sponsor
- Yale University
- Start
- Feb 2022
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and lenvatinib in melanoma, renal cell carcinoma (RCC) and brain metastases (2 cohorts), sponsored by Yale University. Primary endpoint: Best Brain Metastasis Response Rate at 2 years. Started Feb 2022; status: terminated.
02
Drugs
pembrolizumablenvatinib
03
Conditions
melanomarenal cell carcinoma (RCC)brain metastases
Beyond the preview
Go deeper on NCT04955743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04955743.